Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer.

Objective: To evaluate the relationship between the body mass index (BMI) and serum testosterone concentrations in men receiving luteinizing hormone-releasing hormone (LHRH) agonist therapy for prostate cancer.

Materials And Methods: A total of 66 white men were included in the present study. All subjects had received LHRH agonist therapy for ≥ 3 months.